- Home
- DVAX vs GKOS Comparison
DVAX vs GKOS Comparison
Compare DVAX & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- GKOS
- Stock Information
- Founded
- DVAX 1996
- GKOS 1998
- Country
- DVAX United States
- GKOS United States
- Employees
- DVAX N/A
- GKOS N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- GKOS Medical/Dental Instruments
- Sector
- DVAX Health Care
- GKOS Health Care
- Exchange
- DVAX Nasdaq
- GKOS Nasdaq
- Market Cap
- DVAX N/A
- GKOS 5.1B
- IPO Year
- DVAX 2004
- GKOS 2015
- Fundamental
- Price
- DVAX $10.44
- GKOS $88.33
- Analyst Decision
- DVAX Hold
- GKOS Strong Buy
- Analyst Count
- DVAX 3
- GKOS 13
- Target Price
- DVAX $24.67
- GKOS $155.00
- AVG Volume (30 Days)
- DVAX 2.6M
- GKOS 987.1K
- Earning Date
- DVAX 05-07-2025
- GKOS 04-30-2025
- Dividend Yield
- DVAX N/A
- GKOS N/A
- EPS Growth
- DVAX N/A
- GKOS N/A
- EPS
- DVAX 0.20
- GKOS N/A
- Revenue
- DVAX $277,246,000.00
- GKOS $383,481,000.00
- Revenue This Year
- DVAX $20.07
- GKOS $27.84
- Revenue Next Year
- DVAX $18.34
- GKOS $27.99
- P/E Ratio
- DVAX $51.30
- GKOS N/A
- Revenue Growth
- DVAX 19.36
- GKOS 21.85
- 52 Week Low
- DVAX $9.74
- GKOS $77.91
- 52 Week High
- DVAX $14.63
- GKOS $163.71
- Technical
- Relative Strength Index (RSI)
- DVAX 26.61
- GKOS 39.95
- Support Level
- DVAX $10.84
- GKOS $86.16
- Resistance Level
- DVAX $12.92
- GKOS $94.55
- Average True Range (ATR)
- DVAX 0.58
- GKOS 6.40
- MACD
- DVAX -0.21
- GKOS 1.01
- Stochastic Oscillator
- DVAX 13.38
- GKOS 45.99
About GKOS Glaukos Corporation
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.